Choa Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Choa Yun has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Chung Mo Nam
Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications - Eun-Cheol Park
Institute of Health Services Research, Yonsei University
2 shared publications - Jae Hong Joo
Department of Public Health, Graduate School, Yonsei University, Seoul 03722, Korea
2 shared publications - Minah Park
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA
2 shared publications - Minkyo Song
Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Baltimore, MD, USA
2 shared publications - Soo Hyun Kang
Department of Public Health, Graduate School, Yonsei University, Seoul 03722, Korea
2 shared publications
Latest Publications
- 5 August 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (9) , 4407-4418
Immunoproteomic Profiling of Autoantibodies and Antibodies against Infectious Agents in Autoimmune Diseases
Prior research investigated limited antibody sets within individual autoimmune diseases. Using the Nucleic-Acid Programmable Protein Array platform, we measured antibodies against 280 human, 40 viral, and 15 bacterial antigens in serum from 237 patients with 8 autoimmune diseases, including autoimmune gastritis (AG), autoimmune thyroiditis (AT), celiac disease (CD), idiopathic inflammatory myopathies (IIM), type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE), and 112 controls. Candidate antibodies were identified by combining Firth logistic regression and machine learning. We identified disease-specific antibodies, ranging from 3 in IIM to 13 in SLE for IgG and 1 in CD to 13 in AG for IgA. Additionally, 63 IgG and 44 IgA antibodies were shared across two or more diseases. Notably, two IgG autoantibodies overlapped in up to five diseases: directed against STNM4 (SLE, SjD, T1D, CD, and RA) and TRIM21 (SLE, SjD, IIM, CD, and RA); and three IgA antibodies in up to seven diseases: directed against H1N1 Influenza A virus NP (IIM, SjD, AG, T1D, CD, RA, and AT) and Coxsackievirus B3MK012537 and Enterovirus C PVgp1 (IIM, SjD, AG, T1D, CD, SLE, and RA). These findings underscore the potential of antibody profiling in autoimmune disease characterization and biomarker discovery.
- 5 August 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (9) , 4407-4418
Immunoproteomic Profiling of Autoantibodies and Antibodies against Infectious Agents in Autoimmune Diseases
Prior research investigated limited antibody sets within individual autoimmune diseases. Using the Nucleic-Acid Programmable Protein Array platform, we measured antibodies against 280 human, 40 viral, and 15 bacterial antigens in serum from 237 patients with 8 autoimmune diseases, including autoimmune gastritis (AG), autoimmune thyroiditis (AT), celiac disease (CD), idiopathic inflammatory myopathies (IIM), type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), Sjögren’s disease (SjD), and systemic lupus erythematosus (SLE), and 112 controls. Candidate antibodies were identified by combining Firth logistic regression and machine learning. We identified disease-specific antibodies, ranging from 3 in IIM to 13 in SLE for IgG and 1 in CD to 13 in AG for IgA. Additionally, 63 IgG and 44 IgA antibodies were shared across two or more diseases. Notably, two IgG autoantibodies overlapped in up to five diseases: directed against STNM4 (SLE, SjD, T1D, CD, and RA) and TRIM21 (SLE, SjD, IIM, CD, and RA); and three IgA antibodies in up to seven diseases: directed against H1N1 Influenza A virus NP (IIM, SjD, AG, T1D, CD, RA, and AT) and Coxsackievirus B3MK012537 and Enterovirus C PVgp1 (IIM, SjD, AG, T1D, CD, SLE, and RA). These findings underscore the potential of antibody profiling in autoimmune disease characterization and biomarker discovery.
- Open Access
- 4 February 2026
- Published by Elsevier in SSRN Electronic Journal
The Interplay of Inherited Chromosomally Integrated Human Herpesvirus 6, Telomere Length, and the Metabolome in Autoimmune Disease Incidence: Evidence from the UK Biobank Study
Autoimmune diseases arise from failures in immune regulation and increase with biological aging. Inherited chromosomally integrated human herpesvirus-6 (iciHHV-6) represents a unique model of lifelong viral exposure, as the viral genome is embedded within host telomeres and may influence leukocyte telomere length (LTL), a marker of immune aging. Circulating metabolites may further shape these viral-telomeric interactions. Using 156,927 UK Biobank participants free of autoimmune disease at baseline, we examined associations between iciHHV-6, LTL, and incident autoimmune disease, and evaluated metabolomic pathways that mediate or modify these relationships. Over follow-up, autoimmune disease incidence was 7.8%, and iciHHV-6 prevalence was 1.3%. iciHHV-6 carrier status was not directly associated with autoimmune disease risk despite higher comorbidity burden. Longer LTL was independently protective overall, particularly for rheumatoid arthritis, although it was positively associated with multiple sclerosis. iciHHV-6 carriers exhibited longer LTL, resulting in a small but significant indirect protective effect on autoimmune disease risk. LTL also moderated viral effects, with stronger protection among iciHHV-6-positive individuals, suggesting telomere length buffers adverse viral-immune interactions. Metabolomic analyses revealed that triglyceride-rich lipoproteins and pro-inflammatory lipids were associated with shorter LTL and higher autoimmune risk, whereas omega-3 fatty acids, albumin, and HDL phospholipids were protective. Lipidomic pathways mediated a meaningful proportion of the LTL-autoimmune association and modified viral effects. Together, these findings support a telomere-lipid-immunity axis linking viral integration, metabolic aging, and autoimmune susceptibility.
- 4 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Interplay of Inherited Chromosomally Integrated Human Herpesvirus 6, Telomere Length, and the Metabolome in Autoimmune Disease Incidence: Evidence from the UK Biobank Study
Autoimmune diseases arise from failures in immune regulation and increase with biological aging. Inherited chromosomally integrated human herpesvirus-6 (iciHHV-6) represents a unique model of lifelong viral exposure, as the viral genome is embedded within host telomeres and may influence leukocyte telomere length (LTL), a marker of immune aging. Circulating metabolites may further shape these viral-telomeric interactions. Using 156,927 UK Biobank participants free of autoimmune disease at baseline, we examined associations between iciHHV-6, LTL, and incident autoimmune disease, and evaluated metabolomic pathways that mediate or modify these relationships. Over follow-up, autoimmune disease incidence was 7.8%, and iciHHV-6 prevalence was 1.3%. iciHHV-6 carrier status was not directly associated with autoimmune disease risk despite higher comorbidity burden. Longer LTL was independently protective overall, particularly for rheumatoid arthritis, although it was positively associated with multiple sclerosis. iciHHV-6 carriers exhibited longer LTL, resulting in a small but significant indirect protective effect on autoimmune disease risk. LTL also moderated viral effects, with stronger protection among iciHHV-6-positive individuals, suggesting telomere length buffers adverse viral-immune interactions. Metabolomic analyses revealed that triglyceride-rich lipoproteins and pro-inflammatory lipids were associated with shorter LTL and higher autoimmune risk, whereas omega-3 fatty acids, albumin, and HDL phospholipids were protective. Lipidomic pathways mediated a meaningful proportion of the LTL-autoimmune association and modified viral effects. Together, these findings support a telomere-lipid-immunity axis linking viral integration, metabolic aging, and autoimmune susceptibility.
- Open Access
- 17 September 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 11, 100315
Immune responses to infection and autoimmune diseases in the UK biobank
- 17 September 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 11, 100315
Open AccessImmune responses to infection and autoimmune diseases in the UK biobank
- Open Access
- 30 March 2023
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 9 (1) , e39904
Regional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model
Background: There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. Objective: This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. Methods: This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. Results: Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. Conclusions: Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.
- 30 March 2023
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 9 (1) , e39904
Open AccessRegional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model
Background: There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. Objective: This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. Methods: This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. Results: Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. Conclusions: Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (19) , e141
The Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea
Hyun DG, et al. J Korean Med Sci. 2023 Apr;38(19):e141. https://doi.org/10.3346/jkms.2023.38.e141
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (19) , e141
Open AccessThe Profile of Early Sedation Depth and Clinical Outcomes of Mechanically Ventilated Patients in Korea
Hyun DG, et al. J Korean Med Sci. 2023 Apr;38(19):e141. https://doi.org/10.3346/jkms.2023.38.e141
- Open Access
- 27 May 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Regional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model (Preprint)
BACKGROUND There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. OBJECTIVE This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. METHODS This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. RESULTS Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. CONCLUSIONS Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.
- 27 May 2022
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessRegional Differences in Medical Costs of Chronic Kidney Disease in the South Korean Population: Marginalized Two-Part Model (Preprint)
BACKGROUND There are regional gaps in the access to medical services for patients with chronic kidney disease (CKD), and it is necessary to reduce those gaps, including the gaps involving medical costs. OBJECTIVE This study aimed to analyze regional differences in the medical costs associated with CKD in the South Korean population. METHODS This longitudinal cohort study included participants randomly sampled from the National Health Insurance Service-National Sample Cohort of South Korea. To select those who were newly diagnosed with CKD, we excluded those who were diagnosed in 2002-2003 and 2018-2019. A total of 5903 patients with CKD were finally included. We used a marginalized two-part longitudinal model to assess total medical costs. RESULTS Our cohort included 4775 (59.9%) men and 3191 (40.1%) women. Of these, 971 (12.2%) and 6995 (87.8%) lived in medically vulnerable and nonvulnerable regions, respectively. The postdiagnosis costs showed a significant difference between the regions (estimate: –0.0152, 95% confidence limit: –0.0171 to –0.0133). The difference in medical expenses between the vulnerable and nonvulnerable regions showed an increase each year after the diagnosis. CONCLUSIONS Patients with CKD living in medically vulnerable regions are likely to have higher postdiagnostic medical expenses compared to those living in regions that are not medically vulnerable. Efforts to improve early diagnosis of CKD are needed. Relevant policies should be drafted to decrease the medical costs of patients with CKD disease living in medically deprived areas.